Compare BOF & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BOF | CTSO |
|---|---|---|
| Founded | 2017 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Medical/Dental Instruments |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.4M | 45.7M |
| IPO Year | 2023 | 2008 |
| Metric | BOF | CTSO |
|---|---|---|
| Price | $4.04 | $0.69 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | ★ 87.4K | 69.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.36 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $3,184,018.00 | ★ $22,503,908.00 |
| Revenue This Year | N/A | $7.29 |
| Revenue Next Year | N/A | $8.91 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 258.20 | 48.53 |
| 52 Week Low | $1.53 | $0.60 |
| 52 Week High | $4.95 | $1.39 |
| Indicator | BOF | CTSO |
|---|---|---|
| Relative Strength Index (RSI) | 57.21 | 44.69 |
| Support Level | $2.85 | $0.62 |
| Resistance Level | $4.95 | $0.74 |
| Average True Range (ATR) | 0.31 | 0.05 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 44.59 | 26.35 |
Branchout Food inc is engaged in the development, marketing, sale, and distribution of plant-based, dehydrated fruit and vegetable snacks and powders. Its products are currently manufactured for the company by contract manufacturers based in South America and North America that produce dehydrated fruit and vegetable products for the company using a new proprietary dehydration technology that it licenses from a third party. The Company's customers are located throughout the United States. Its current primary products are BranchOut Snacks, BranchOut Powders, and BranchOut Industrial Ingredients.
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.